Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the recipient of a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 455,184 shares, an increase of 1,589.7% from the June 30th total of 26,939 shares. Currently, 29.4% of the company’s stock are short sold. Based on an average daily trading volume, of 925,479 shares, the short-interest ratio is currently 0.5 days.

Scinai Immunotherapeutics Stock Down 6.9%

Shares of SCNI traded down $0.02 during trading hours on Friday, hitting $0.23. The company had a trading volume of 35,206 shares, compared to its average volume of 541,542. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $910,800.00, a PE ratio of -0.22 and a beta of 2.11. Scinai Immunotherapeutics has a one year low of $0.21 and a one year high of $3.48. The company’s fifty day moving average price is $0.34 and its two-hundred day moving average price is $0.60.

Institutional Trading of Scinai Immunotherapeutics

An institutional investor recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC increased its position in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the quarter. Citadel Advisors LLC owned about 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent SEC filing. 58.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.